AIF1 and B-cell non-Hodgkin lymphoma: Regarding the IPT, while T-cell lymphomas showed a significant reduction in the number of Iba1 positively immunolabeled cells with respect to B-cell lymphomas, the contrary was found when the number of cells immunostained with the MAC387 antibody was assessed (Figure 1B and Figure 3).